Suppr超能文献

小肠细菌过度生长是肝硬化患者高动力循环的病因吗?

Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?

作者信息

Maslennikov Roman, Pavlov Chavdar, Ivashkin Vladimir

机构信息

Department of Gastroenterology and Hepatology, Sechenov University, Moscow, Russia.

出版信息

Turk J Gastroenterol. 2019 Nov;30(11):964-975. doi: 10.5152/tjg.2019.18551.

Abstract

BACKGROUND/AIMS: Small intestinal bacterial overgrowth (SIBO) and hemodynamic changes are common in cirrhosis. We wanted to examine our hypothesis whether SIBO leads to hemodynamic changes in cirrhosis.

MATERIALS AND METHODS

A total of 50 patients with cirrhosis and 15 healthy controls were enrolled in a pilot prospective study. All participants underwent the lactulose hydrogen breath test for SIBO and echocardiography with a simultaneous assessment of blood pressure and heart rate. Cardiac output and systemic vascular resistance were calculated.

RESULTS

Study participants with SIBO had a lower systolic blood pressure and systemic vascular resistance compared to those without SIBO and to healthy controls (110.2±12.3 mmHg vs. 126.2±21.0 mmHg and 121.2±9.8 mmHg; p=0.005 and p=0.011, respectively; 1312±352 dyn•s•cm-5 vs. 1704±424 dyn•s•cm-5 and 1648±272 dyn•s•cm-5; p=0.001 and p=0.006, respectively), but a higher cardiac output (5.38±1.41 l/min vs. 4.52±1.03 l/min and 4.40±0.68 l/min; p=0.034 and p=0.041, respectively) and C-reactive protein (10.5[1.2-16.5] mg/l vs. 2.8[0.6-9.1] mg/l; p=0.028; no comparison with healthy controls). There were no significant differences between patients without SIBO and healthy controls with regard to systolic blood pressure (p=0.554), systemic vascular resistance (p=0.874), and cardiac output (p=0.795). SIBO was associated with vasodilation and hyperdynamic circulation in decompensated cirrhosis (p=0.002; p=0.012), but not in compensated cirrhosis (p=1.000; p=0.474).

CONCLUSIONS

SIBO is associated with hyperdynamic circulation and other hemodynamic changes in cirrhosis and may be a principal factor causing these through systemic inflammation.

摘要

背景/目的:小肠细菌过度生长(SIBO)和血流动力学改变在肝硬化患者中很常见。我们想要验证我们的假设,即SIBO是否会导致肝硬化患者的血流动力学改变。

材料与方法

一项前瞻性试点研究纳入了50例肝硬化患者和15例健康对照者。所有参与者均接受了用于检测SIBO的乳果糖氢呼气试验以及超声心动图检查,并同时评估血压和心率。计算心输出量和全身血管阻力。

结果

与无SIBO的患者及健康对照者相比,患有SIBO的研究参与者收缩压和全身血管阻力更低(分别为110.2±12.3 mmHg vs. 126.2±21.0 mmHg和121.2±9.8 mmHg;p = 0.005和p = 0.011;1312±352 dyn•s•cm-5 vs. 1704±424 dyn•s•cm-5和1648±272 dyn•s•cm-5;p = 0.001和p = 0.006),但心输出量更高(分别为5.38±1.41 l/min vs. 4.52±1.03 l/min和4.40±0.68 l/min;p = 0.034和p = 0.041),C反应蛋白水平也更高(10.5[1.2 - 16.5] mg/l vs. 2.8[0.6 - 9.1] mg/l;p = 0.028;未与健康对照者比较)。在收缩压(p = 0.554)、全身血管阻力(p = 0.874)和心输出量(p = 0.795)方面,无SIBO的患者与健康对照者之间无显著差异。SIBO与失代偿期肝硬化的血管舒张和高动力循环相关(p = 0.002;p = 0.012),但与代偿期肝硬化无关(p = 1.000;p = 0.474)。

结论

SIBO与肝硬化患者的高动力循环及其他血流动力学改变相关,可能是通过全身炎症导致这些改变的主要因素。

相似文献

1
Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?
Turk J Gastroenterol. 2019 Nov;30(11):964-975. doi: 10.5152/tjg.2019.18551.
3
Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.
Hepatol Int. 2018 Nov;12(6):567-576. doi: 10.1007/s12072-018-9898-2. Epub 2018 Oct 4.
4
Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication.
Am J Gastroenterol. 2008 May;103(5):1257-62. doi: 10.1111/j.1572-0241.2007.01758.x. Epub 2008 Apr 16.
5
Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients.
Dig Dis Sci. 2010 May;55(5):1465-71. doi: 10.1007/s10620-009-0870-9. Epub 2009 Jun 11.
6
Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.
J Clin Gastroenterol. 2015 Aug;49(7):571-6. doi: 10.1097/MCG.0000000000000257.
7
Orocecal transit time and small intestinal bacterial overgrowth in type 2 diabetes patients from North India.
Diabetes Technol Ther. 2011 Nov;13(11):1115-20. doi: 10.1089/dia.2011.0078. Epub 2011 Jul 19.
8
Hemodynamic studies in acute-on-chronic liver failure.
Dig Dis Sci. 2009 Apr;54(4):869-78. doi: 10.1007/s10620-008-0421-9. Epub 2008 Aug 9.
9
Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis.
Asia Pac J Clin Nutr. 2016;25(2):283-91. doi: 10.6133/apjcn.2016.25.2.06.

引用本文的文献

1
Gut microbiota in liver diseases: initiation, development and therapy.
Front Med (Lausanne). 2025 Jun 4;12:1615839. doi: 10.3389/fmed.2025.1615839. eCollection 2025.
3
Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.
Int J Mol Sci. 2024 Feb 6;25(4):1988. doi: 10.3390/ijms25041988.
5
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
Int J Mol Sci. 2023 Nov 19;24(22):16502. doi: 10.3390/ijms242216502.
6
Gut Dysbiosis and Hemodynamic Changes as Links of the Pathogenesis of Complications of Cirrhosis.
Microorganisms. 2023 Aug 31;11(9):2202. doi: 10.3390/microorganisms11092202.
7
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.
World J Gastroenterol. 2023 Jul 21;29(27):4236-4251. doi: 10.3748/wjg.v29.i27.4236.
8
Epidemiology of small intestinal bacterial overgrowth.
World J Gastroenterol. 2023 Jun 14;29(22):3400-3421. doi: 10.3748/wjg.v29.i22.3400.
9
Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis.
Microorganisms. 2023 Apr 13;11(4):1017. doi: 10.3390/microorganisms11041017.

本文引用的文献

1
Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease.
Semin Liver Dis. 2017 Nov;37(4):388-400. doi: 10.1055/s-0037-1608832. Epub 2017 Dec 22.
2
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Am J Gastroenterol. 2017 May;112(5):775-784. doi: 10.1038/ajg.2017.46. Epub 2017 Mar 21.
4
Minimally invasive or noninvasive cardiac output measurement: an update.
J Anesth. 2016 Jun;30(3):461-80. doi: 10.1007/s00540-016-2154-9. Epub 2016 Mar 9.
5
How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach.
Curr Gastroenterol Rep. 2016 Feb;18(2):8. doi: 10.1007/s11894-015-0482-9.
6
Markers of bacterial translocation in end-stage liver disease.
World J Hepatol. 2015 Sep 18;7(20):2264-73. doi: 10.4254/wjh.v7.i20.2264.
9
Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.
Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验